OCULAR THERAPEUTIX, INC Operating Lease, Expense
OCULAR THERAPEUTIX, INC (OCUL) reported Operating Lease, Expense of $2.23 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2020-03-12
- OCULAR THERAPEUTIX, INC operating lease, expense for fiscal 2019 was $2.23M, a 24.50% increase from fiscal 2018.
- OCULAR THERAPEUTIX, INC operating lease, expense for fiscal 2018 was $1.79M, a 3.17% increase from fiscal 2017.
- OCULAR THERAPEUTIX, INC operating lease, expense for fiscal 2017 was $1.73M.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2019-12-31 | $2.23M 10-K · filed 2020-03-12 |
| 2018-12-31 | $1.79M 10-K · filed 2020-03-12 |
| 2017-12-31 | $1.73M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |